ClinicalTrials.gg
RecruitingNCT05902078EFFECTUpdated May 16, 2024

Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis

A Phase 4 interventional study of Eldecalcitol capsules and Calcitriol capsules in Low Bone Mineral Density and Postmenopausal Osteoporosis, sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Recruiting at 21 sites in China. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.

Primary conditionOsteoporosis, PostmenopausalRegistry: Bone Diseases, MetabolicReclassifiedWhy we changed it
Registry
Bone Diseases, Metabolic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis, Postmenopausal
Why
  1. The study's listed conditions name Osteoporosis, Postmenopausal, a narrower term within Bone Diseases, Metabolic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Osteoporosis, Postmenopausal with a site in China — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · China.

Planned enrollment
6th of 21
300 · median 148
Started
2023
with 1 other
Phase 4
3 of 25
1 open now
Registered
25th of 25
by date

Among the 25 studies in Osteoporosis, Postmenopausal with a site in China, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 4, and was the 25th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 25 studies in Osteoporosis, Postmenopausal with a site in China is open now.

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Osteoporosis, Postmenopausal with a site in China, or all of them as a file.
02

Study summary

To investigate the efficacy and safety of eldecalcitol in postmenopausal women with low bone mineral density (BMD) or mild osteoporosis through a randomized, open-label, parallel controlled trial with calcitriol as the control.

Read the detailed description

Postmenopausal women with low bone mineral density (BMD) or mild osteoporosis will be randomized in a 1:1 ratio to receive open-label oral 0.75μg eldecalcit daily or open-label oral 0.5μg calcitriol daily for 12 months.

03

Conditions studied

  • Low Bone Mineral Density
  • Postmenopausal Osteoporosis

Browse trials for

04

In context

Osteoporosis, Postmenopausal Reclassified

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's planned enrollment of 300 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

Shanghai Jiao Tong University Affiliated Sixth People's Hospital is the lead sponsor of 41 studies on the registry; 23 are open to participants now.

Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women (based on medical history) aged 50 or older and menopause time more than 2 years. If there is uncertainty regarding menopausal status, women 60 years of age and older will be considered postmenopausal.
  2. BMD (determined by DXA) of lumbar L1-4 or total hip or femoral neck met one of the following conditions at screening:
  1. low BMD: -2.5\<T\< -1.0, without vertebral and fragility fracture history 2) mild osteoporosis: T≤-2.5, without vertebral and fragility fracture history 3. Ambulatory outpatients 4. Written

Exclusion criteria

Exclusion Criteria:

  1. Severe vitamin D deficiency at screening (defined as serum 25OHD\<10 ng/ml);Vitamin D repletion will be permitted and dosage will be at the discretion of investigators and subjects may be re-screened
  2. Primary hyperparathyroidism, Cushing's syndrome, hyperthyroidism, gonadal insufficiency, osteogenesis impotence, rheumatoid arthritis, poorly controlled diabetes mellitus (>9%), or other conditions that can cause secondary osteoporosis, or treatment with in the 2 months prior to study entry
  3. Had injected bisphosphonate once or more within 3 years before entering the study; or had received oral bisphosphonate oral for 6 months or more in the 3 years prior to study entry; or had received parathyroid hormone once or more in the 3 years before entering the study; or received 2 weeks or more of calcitonin or vitamin K or active vitamin D or selective estrogen receptor modulator or hormone replacement therapy or traditional Chinese medicine for bone pine within 2 months prior to study entry; or received subcutaneous anti-RANKL antibody at any time prior to study entry
  4. Urolithiasis at screening
  5. Hypercalcemia (serum calcium >10.4 mg/dL), or hypercalciuria (urine calcium>400 mg/gCr), or hyperuricemia (above 420 μmol/L in men and 360 μmol/L in women)
  6. Severe liver disease such as cirrhosis or serious heart disease such as severe heart failure
  7. Active malignant tumors or a history of malignant tumors within 5 years before obtained
  8. History of allergy to vitamin D
  9. Any condition which in the opinion of the investigator unfit for the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Eldecalcitol

    Participants receive oral eldecalcitol 0.75μg daily for 12 months

    Drug: Eldecalcitol capsules

  • Active comparator
    Calcitriol

    Participants receive oral calcitriol 0.5μg daily for 12 months

    Drug: Calcitriol capsules

Interventions

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine

    Bone mineral density will be measured using dual energy x-ray absorptiometry (DXA). Images will be analyzed by a central imaging reader.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. Percent Change From Baseline at Month 6 in BMD at the Lumbar Spine

    Bone mineral density will be measured using dual energy x-ray absorptiometry (DXA). Images will be analyzed by a central imaging reader.

    Time frame: Baseline to 6 months

  2. Percent Change From Baseline at Month 6 in BMD of the Total Hip

    Bone mineral density will be measured using dual energy x-ray absorptiometry (DXA). Images will be analyzed by a central imaging reader.

    Time frame: Baseline to 6 months

  3. Percent Change From Baseline at Month 6 in BMD of the Femoral Neck

    Bone mineral density will be measured using dual energy x-ray absorptiometry (DXA). Images will be analyzed by a central imaging reader.

    Time frame: Baseline to 6 months

  4. Percent Change From Baseline at Month 12 in BMD of the Total Hip

    Bone mineral density will be measured using dual energy x-ray absorptiometry (DXA). Images will be analyzed by a central imaging reader.

    Time frame: Baseline to 6 months

  5. Percent Change From Baseline at Month 12 in BMD of the Femoral Neck

    Bone mineral density will be measured using dual energy x-ray absorptiometry (DXA). Images will be analyzed by a central imaging reader.

    Time frame: Baseline to 12 months

  6. Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)

    Serum P1NP will be determined

    Time frame: Baseline and months 6 and 12

  7. Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)

    Serum CTX will be determined

    Time frame: Baseline and months 6 and 12

  8. Percent Change From Baseline in Parathyroid Hormone (PTH)

    Serum PTH will be determined

    Time frame: Baseline and months 6 and 12

  9. Percent Change From Baseline in 25-Hydroxyvitamin D [25(OH)D]

    Serum 25(OH)D will be determined

    Time frame: Baseline and months 6 and 12

  10. Incidence of new vertebral fracture

    New vertebral fracture will be confirmed by the lateral X-ray of thoracic/lumbar vertebrae

    Time frame: Baseline and months 12

08

Study locations

1 of 21 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jun 2025, 21 months after the start.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 13, 2023
StartActual
Sep 27, 2023
Primary completionEst.
Jun 2025
CompletionEst.
Dec 2025
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05902078
Lead sponsor
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Collaborators
Chugai Pharma China Co., Ltd.
Responsible party
Zhenlin Zhang, MD (Chief Physician, Shanghai Jiao Tong University Affiliated Sixth People's Hospital) — Principal investigator
First posted
Jun 13, 2023
Start date
Sep 27, 2023
Primary completion
Jun 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
May 16, 2024

Study contacts

Li Shen
Contact
shenli_0510@126.com
(+86)15800674978
Zhenlin Zhang
principal investigator · Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eldecalcitol

Start the discussion